



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

: Confirmation No. 7196

Tetsunori FUJISAWA et al.

: Docket No. 2000_0562A

Serial No. 09/581,402

: Group Art Unit 1634

Filed June 12, 2000

: Examiner Jeffrey N. Fredman

NOVEL METALLOPROTEINASE INHIBITORS

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT

PATENT OFFICE FEE TRANSMITTAL FORM NO. 23-0975.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Attached hereto is a check in the amount of \$2,010.00 to cover Patent Office fees relating to filing the following attached papers:

Petition for Extension of Time (5 month) \$2,010.00

Other: \$

A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.


Respectfully submitted,

Tetsunori FUJISAWA et al.

By Warren M. Cheek, Jr.
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
June 8, 2004

[Check No. 62192]
2000_0562A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **Confirmation No. 7196**
Tetsunori FUJISAWA et al. : Docket No. 2000_0562A
Serial No. 09/581,402 : Group Art Unit 1634
Filed June 12, 2000 : Examiner Jeffrey N. Fredman

NOVEL METALLOPROTEINASE INHIBITORS

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

RESPONSE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is responsive to the Official Action dated December 8, 2003, the time for responding thereto being extended for five months in accordance with a petition for extension submitted concurrently herewith.

The Official Action constitutes a requirement for restriction.

Applicants elect to prosecute the invention of "Groups 1-34, claims 23-25, drawn to enzyme inhibitor compounds".

This response is made with traverse.

The restriction requirement is unduly burdensome and does not comply with PTO practice. The claimed compounds have a common core and common activity.

Moreover, restriction is improper because the present claims were added in Applicants' last response as a result of the direct invitation of the Examiner to do so. See the paragraph bridging pages 2-3 of the Action dated April 14, 2003.

Favorable reconsideration and withdrawal of the restriction requirement is solicited.

Respectfully submitted,

Tetsunori FUJISAWA et al.

By: Warren M. Cheek
Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
June 8, 2004